TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms

: Schimmer Roman R, Kovtonyuk Larisa V, Klemm Nancy, Fullin Jonas, Stolz Sebastian M, Mueller Jan, Caiado Francisco, Kurppa Kari J, Ebert Benjamin L, Manz Markus G, Boettcher Steffen

Publisher: Elsevier

: 2022

: Blood Advances

: BLOOD ADVANCES

: BLOOD ADV

: 6

: 11

: 3201

: 3206

: 6

: 2473-9537

DOI: https://doi.org/10.1182/bloodadvances.2021005859

: https://doi.org/10.1182/bloodadvances.2021005859

: https://research.utu.fi/converis/portal/detail/Publication/176305725